Deep brain stimulation
This collaborative clinical research group focuses on identifying potential mechanisms of action of deep brain stimulation (DBS), given the favorable neuropsychologic and psychiatric outcomes observed among patients with Parkinson's disease. Areas of study include neural circuitry, neurotransmission and synaptic plasticity.
Functional neuromodulation, such as deep brain stimulation, offers opportunity for surgical treatment of refractory psychiatric disorders. Several therapeutic trials have been conducted to investigate the effectiveness of DBS in the treatment of refractory depression, obsessive-compulsive disorder and Tourette syndrome.
Currently the group is part of a multicenter, controlled trial of deep brain stimulation for obsessive-compulsive disorder. Future plans include a clinical trial of deep brain stimulation for treating refractory depression.
- Osama A. Abulseoud, M.D., is studying the impact of comorbid alcoholism on mania phenotypes and has successfully induced manic-like behavioral phenotypes in two types of rats. He has also identified a novel mechanism of action of DBS in reducing ethanol consumption through regulation of circadian rhythm genes in the nucleus accumbens.
- Clinically, the group is studying the impact of emotional or behavioral induction during subthalamic DBS parameter optimization in patients with Parkinson's disease. This includes effect on mood disorders and overall quality of life.
- Osama A. Abulseoud, M.D.
- Andrea C. Adams, M.D.
- Mark A. Frye, M.D.
- Kendall H. Lee, M.D., Ph.D.
- Joseph Y. Matsumoto, M.D.
- Jarrett W. Richardson, M.D.
- Shirlene Sampson, M.D.
- Paola Sandroni, M.D., Ph.D.
- Glenn E. Smith, Ph.D., L.P.
- Squire M. Stead, M.D., Ph.D.
- Susannah J. Tye, Ph.D.
- Christopher A. Wall, M.D.
|Investigator & Role
|Osama A. Abulseoud, M.D., principal investigator
||Preclinical Glutamate Modulation Through Deep Brain Stimulation as a Novel Target for Alcohol Addiction
||Mayo Clinic Center for Translational Science Activities KL2 Mentored Career Development Award
See publications by deep brain stimulation researchers on PubMed:
- Kasasbeh A, Abulseoud OA, Matsumoto JY, Stead SM, Goerss SJ, Klassen BT, Huston J 3rd, Min HK, Lee KH, Frye MA. Lack of differential motor outcome with subthalamic nucleus region stimulation in Parkinson's disease. Journal of Clinical Neuroscience. 2013;20:1520.
- Kim JP, Min HK, Knight EJ, Duffy PS, Abulseoud OA, Marsh MP, Kelsey K, Blaha CD, Bennet KE, Frye MA, Lee KH. Centromedian-parafascicular deep brain stimulation induces differential functional inhibition of the motor, associative, and limbic circuits in large animals. Biological Psychiatry. 2013;74:917.
- Knight EJ, Min HK, Hwang SC, Marsh MP, Paek S, Kim I, Felmlee JP, Abulseoud OA, Bennet KE, Frye MA, Lee KH. Nucleus accumbens deep brain stimulation results in insula and prefrontal activation: A large animal FMRI study. PLOS One. 2013;8:e56640.
- Chopra A, Abulseoud OA, Sampson S, Lee KH, Klassen BT, Fields JA, Matsumoto JY, Adams A, Stoppel CJ, Geske J. Mood stability in Parkinson's disease following deep brain stimulation: A 6-month prospective follow-up study. Psychonomics. In press. Accessed [12/31/2013].
- Kouzani AZ, Abulseoud OA, Tye SJ, Hosain K, Berk M. A low power micro deep brain stimulation device for laboratory animals. IEEE Journal of Translational Engineering in Health and Medicine. In press. Accessed [12/31/2013].
Non-DBS related papers
- Abulseoud OA, Camsari MU, Ruby CL, Kasabeh A, Choi S, Choi DS. Attenuation of ethanol withdrawal by ceftriaxone-induced upregulation of glutamate transporter EAAt2. Neuropsychopharmacology. In press. Accessed [12/31/2013].
- Abulseoud OA, Karpyak VM, Schneekloth T, Hall-Flavin DK, Loukianova LL, Geske JR, Biernacka JM, Mrazek DA, Frye MA. A retrospective study of gender differences in depressive symptoms and risk of relapse in patients with alcohol dependence. American Journal on Addictions. 2013;22:437.
- Abulseoud OA, Ahmed AT, Nassi S, Vigen C. Thyroid stimulating hormone in acute psychiatric patients with positive urine toxicology: A retrospective study. Journal of Alcoholism and Drug Dependence. 2013;1:119.
- Abulseoud OA, Miller JD, Wu J, Choi DS, Holschneider DP. Ceftriaxone upregulates the glutamate transporter in medial prefrontal cortex and blocks reinstatement of methamphetamine seeking in a condition place preference paradigm. Brain Research. 2012;1456:14.
- Abulseoud OA, Gitlin M, Altshuler L, Frye MA. Baseline thyroid indices and the subsequent response to citalopram treatment, a pilot study. Brain and Behavior. 2013;3:89.
- Karpyak VM, Winham SJ, Preuss UW, Zill P, Cunningham JM, Walker DL, Lewis KA, Geske JR, Colby CL, Abulseoud OA, Hall-Flavin DK, Loukianova LL, Schneekloth TD, Frye MA, Bazov I, Heit JA, Bakalkin G, Mrazek DA, Biernacka JM. Association of the PDYN gene with alcohol dependence and the propensity to drink in negative emotional states. International Journal of Neuropsychopharmacology. 2013;16:975.
- Lingwood MD, Siaw TA, Sailasuta N, Abulseoud OA, Chan HR, Ross BD, Bhattacharya P, Han S. Hyperpolarized water as an MR imaging contrast agent: Feasibility of in vivo imaging in a rat model. Radiology. 2012;265:418.
- Karpyak VM, Winham SJ, Biernacka JM, Cunningham JM, Lewis KA, Geske JR, Colby CL, Abulseoud OA, Hall-Flavin DK, Loukianova LL, Schneekloth TD, Frye MA, Heit JA, Mrazek DA. Association of GATA4 sequence variation with alcohol dependence. Addiction Biology. In press. Accessed [12/31/2013].